| [1] |
Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy[J]. Wound Repair Regen, 2009, 17(6): 763-771.
|
| [2] |
Price P, Harding K. The impact of foot complications on health-related quality of life in patients with diabetes[J]. J Cutan Med Surg, 2000, 4(1): 45-50.
|
| [3] |
Escandon J, Vivas AC, Tang J, et al. High mortality in patients with chronic wounds[J]. Wound Repair Regen, 2011, 19(4): 526-528.
|
| [4] |
Mouritzen MV, Abourayale S, Ejaz R, et al. Neurotensin, substance P, and insulin enhance cell migration[J]. J Pept Sci, 2018, 24(7): e3093.
|
| [5] |
Haalboom M. Chronic Wounds: Innovations in Diagnostics and Therapeutics[J]. Curr Med Chem, 2018, 25(41): 5772-5781.
|
| [6] |
Adamová Z, Adam Z. Psychological influences on wound healing[J]. Rozhl Chir, 2019, 98(8): 312-314.
|
| [7] |
张玲玲，魏伟. 治疗自身免疫病药物研究进展[J]. 中国药理学通报，2019, 35(2): 149-156.
|
| [8] |
Shanmugam VK, Schilling A, Germinario A, et al. Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre[J]. Int Wound J, 2012, 9(4): 403-411.
|
| [9] |
Shanmugam VK, Steen VD, Cupps TR. Lower extremity ulcers in connective tissue disease[J]. Isr Med Assoc J, 2008, 10(7): 534-536.
|
| [10] |
Shanmugam VK, Price P, Attinger CE, et al. Lower extremity ulcers in systemic sclerosis: features and response to therapy[J]. Int J Rheumatol, 2010, 2010: 747946.
|
| [11] |
Shanmugam VK, DeMaria DM, Attinger CE. Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression[J]. Clin Rheumatol, 2011, 30(6): 849-853.
|
| [12] |
Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms[J]. J Invest Dermatol, 2007, 127(3): 514-525.
|
| [13] |
Ehrlich MR. Vasculitic ulcers: a complication of collagen-vascular disorders[J]. Ostomy Wound Manage, 1993, 39(1): 12-14, 16-17, 20-22 passim.
|
| [14] |
Beyene RT, Derryberry SL Jr, Barbul A. The Effect of Comorbidities on Wound Healing[J]. Surg Clin North Am, 2020, 100(4): 695-705.
|
| [15] |
Fujimoto M, Asai J, Asano Y, et al. Wound, pressure ulcer and burn guidelines - 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers[J]. J Dermatol, 2020, 47(10): 1071-1109.
|
| [16] |
Mimouni D, Ng PP, Rencic A, et al. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche[J]. Br J Dermatol, 2003, 148(4): 789-794.
|
| [17] |
Kumar L, Thapa BR, Sarkar B, et al. Benign cutaneous polyarteritis nodosa in children below 10 years of age--a clinical experience[J]. Ann Rheum Dis, 1995, 54(2): 134-136.
|
| [18] |
Gottrup F, Karlsmark T. Leg ulcers: uncommon presentations[J]. Clin Dermatol, 2005, 23(6): 601-611.
|
| [19] |
Shanmugam VK. Vasculitic Diseases and Prothrombotic States Contributing to Delayed Healing In Chronic Wounds[J]. Curr Dermatol Rep, 2016, 5(4): 270-277.
|
| [20] |
Asano Y, Ihn H, Maekawa T, et al. High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature[J]. Clin Rheumatol, 2006, 25(3): 396-398.
|
| [21] |
Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients[J]. J Am Acad Dermatol, 2004, 51(4): 574-579.
|
| [22] |
Oien RF, H kansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting[J]. Rheumatology (Oxford), 2001, 40(7): 816-820.
|
| [23] |
Sriram S, Sankaralingam R, Mani M, et al. Autologous platelet rich plasma in the management of non-healing vasculitic ulcers[J]. Int J Rheum Dis, 2016, 19(12): 1331-1336.
|
| [24] |
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis[J]. Lancet, 2017, 389(10086): 2328-2337.
|
| [25] |
Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review[J]. Semin Arthritis Rheum, 2006, 36(2): 88-98.
|
| [26] |
Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations[J].J Am Acad Dermatol, 2005, 53(2): 191-212.
|
| [27] |
Kharlamova N, Jiang X, Sherina N, et al. Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology[J]. Arthritis Rheumatol, 2016, 68(3): 604-613.
|
| [28] |
Garner RW, Mowat AG, Hazleman BL. Wound healing after operations of patients with rheumatoid arthritis[J]. J Bone Joint Surg Br, 1973, 55(1): 134-144.
|
| [29] |
Kadota Y, Nishida K, Hashizume K, et al. Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients[J]. Mod Rheumatol, 2016, 26(1): 68-74.
|
| [30] |
Barnard AR, Regan M, Burke FD, et al. Wound healing with medications for rheumatoid arthritis in hand surgery[J]. ISRN Rheumatol, 2012, 2012: 251962.
|
| [31] |
Kojima M, Nakayama T, Kawahito Y, et al. The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach[J]. Mod Rheumatol, 2016, 26(2): 175-179.
|
| [32] |
Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers[J]. Clin Exp Rheumatol, 2010, 28(1 Suppl 57): 81-83.
|
| [33] |
Sanmartí R, Marsal S, Valverde J, et al. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial[J]. Rheumatology (Oxford), 2005, 44(9): 1140-1144.
|
| [34] |
Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, et al. A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 735-741.
|
| [35] |
Deng GM. Pathogenesis of Skin Injury of Systemic Lupus Erythematosus[J]. Curr Rheumatol Rep, 2018, 20(2): 5.
|
| [36] |
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
|
| [37] |
Akita S. Lower Extremity Wounds in Patients With Idiopathic Thrombocytopenic Purpura and Systemic Lupus Erythematosus[J]. Int J Low Extrem Wounds, 2015, 14(3): 224-230.
|
| [38] |
Shanmugam VK, Angra D, Rahimi H, et al. Vasculitic and autoimmune wounds[J].J Vasc Surg Venous Lymphat Disord, 2017, 5(2): 280-292.
|
| [39] |
Yokogawa N, Tanikawa A, Amagai M, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI) [J]. Mod Rheumatol, 2013, 23(2): 318-322.
|
| [40] |
He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1): 141-149.
|
| [41] |
Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials[J]. Ann Rheum Dis, 2012, 71(11): 1833-1838.
|
| [42] |
Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud′s phenomenon[J]. Cochrane Database Syst Rev, 2017, 12(12): CD000467.
|
| [43] |
Gardinali M, Pozzi MR, Bernareggi M, et al. Treatment of Raynaud′s phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis[J]. J Rheumatol, 2001, 28(4): 786-794.
|
| [44] |
Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2011, 70(1): 32-38.
|
| [45] |
Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis[J]. Arthritis Care Res (Hoboken), 2013, 65(9): 1460-1471.
|
| [46] |
Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations[J]. J Rheumatol, 2005, 32(4): 642-648.
|
| [47] |
Deguchi J, Shigematsu K, Ota S, et al. Surgical result of critical limb ischemia due to tibial arterial occlusion in patients with systemic scleroderma[J].J Vasc Surg, 2009, 49(4): 918-923.
|
| [48] |
Alavi A, French LE, Davis MD, et al. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment[J]. Am J Clin Dermatol, 2017, 18(3): 355-372.
|
| [49] |
Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review[J]. J Am Acad Dermatol, 2015, 73(4): 691-698.
|
| [50] |
Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease[J]. Annu Rev Med, 2009, 60: 97-110.
|
| [51] |
Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab[J]. Arch Dermatol, 2011, 147(10): 1203-1205.
|
| [52] |
Morgenstjerne-Schwenck LET, Knudsen JT, Prasad SC. Efficacy and safety of skin grafting in treatment of vasculitic ulcer and pyoderma gangrenosum-A systematic review[J]. Wound Repair Regen, 2021, 29(2): 240-253.
|
| [53] |
Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome[J]. N Engl J Med, 1995, 332(15): 993-997.
|
| [54] |
Francès C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases[J]. Arthritis Rheum, 2005, 52(6): 1785-1793.
|
| [55] |
Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin[J]. J Am Acad Dermatol, 1997, 36(6 Pt 1): 970-982.
|
| [56] |
Sarvis CM. Antiphospholipid antibody syndrome: when wounds won′t heal[J]. Nursing, 2005, 35(9): 24.
|
| [57] |
Pazzola G, Zuily S, Erkan D. The challenge of bleeding in antiphospholipid antibody-positive patients[J]. Curr Rheumatol Rep, 2015, 17(2): 7.
|
| [58] |
Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome[J]. Curr Rheumatol Rep, 2010, 12(1): 40-44.
|
| [59] |
Perniciaro CV, Winkelmann RK, Hunder GG. Cutaneous manifestations of Takayasu′s arteritis. A clinicopathologic correlation[J]. J Am Acad Dermatol, 1987, 17(6): 998-1005.
|
| [60] |
Carlson JA. The histological assessment of cutaneous vasculitis[J]. Histopathology, 2010, 56(1): 3-23.
|
| [61] |
Kawakami T, Okano T, Soma Y. Rituximab therapy for deep toe ulcer with microscopic polyangiitis refractory to corticosteroids and cyclophosphamide[J]. J Dermatol, 2014, 41(2): 191-192.
|